Administration safety
Retatrutide has been studied as a once-weekly subcutaneous injection, but that does not create public-use instructions.
In Lilly clinical studies, retatrutide is taken as a once-weekly subcutaneous injection. Outside a Lilly clinical trial, it is not approved or publicly available, so this page does not provide personal administration instructions.
These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.
Short source quoteagonist of the GIP, GLP-1, and glucagon receptors
Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial
This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.
Short source quoterandomised, double-blind, placebo and active-controlled
Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial
The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.
Short source quote10-fold dosing errors
Lambson et al., JAPhA 2023 compounded semaglutide administration-error case series
This case series supports warnings about vials, syringe units, and self-measured injectable dosing errors.
Short source quotepreparation errors
McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study
This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.
Short source quotecontamination or concentration
Watson et al., Journal of Medical Toxicology 2021 systematic review of compounding errors
This systematic review supports broader warnings about compounding errors, contamination, and concentration risk.
Start with approval status and clinical-trial availability before considering any treatment discussion.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.
Public record review
Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.
